SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
TNI BioTech Acquires the Exclusive Rights to Low Dose Naltrexone and Other Opioid Antagonists for the Treatment of Inflammatory and Ulcerative Diseases of the Bowel